Mbx Biosciences Inc MBX

$55.94 +1.43 (2.62%)

Valuation

Market cap
2,706,748,000
Revenue TTM
$0
Net income TTM
$-86,970,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
855,400
Avg volume
562,476
Day's range
$52.94 – $57.11
Shares out
49,656,000
Stochastic %K
76%
Beta
0.17
Analysts
Strong Buy
Price target
$86.33

Price

Company profile

MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing Imapextide (MBX...

Show more

MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing Imapextide (MBX 1416), a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 2 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.

Industry
Biotechnology
Sector
Healthcare
Phone
317 659 0200
Website
https://mbxbio.com
Address
11711 North Meridian Street, Suite 300, Carmel, United States

Latest news

Stocktwits

Quantumup Oct 29, 10:33 AM
Truist reiterated $MBX Buy-$88 and said--We see favorable risk/reward heading into MBX-4291's (GLP-1/GIP; obesity) 4Q26 readout. [ $VKTX [[ NVO LLY KLRA GPCR ]] Truist added--We believe MBX-4291's potential for differentiation comes from - 1) Once-monthly dosing; 2) Low peak-to-trough drug exposure that aims to improve Gl tolerability; 3) Better adherence relative to weekly injections. In our view, if '4291 achieves our base case of 7-9% weight loss, 0-15% GI-AEs and PK that confirms monthly dosing, we could see shares up +15-25%. While we acknowledge the strength of competitor data (i.e. VK2735, Bero), we believe that a full-package asset that captures a segment of the >$100B obesity market would be value-creating and also attractive to potential large cap buyers.
0 replies
Quantumup Oct 27, 10:07 AM
Citizens reitd $MBX Mkt OP-$86/said--We view MBX 4291 as one of the more differentiated injectable obesity candidates in development, with the preliminary Phase 1 data looking encouraging and a more robust assessment coming this quarter. $NVO VKTX $LLY KLRA GPCR Here's what else Citizens had to say in its note: https://x.com/Quantumup1/status/2115022485326381074?s=20
0 replies
Rayvio_News_Filter Oct 26, 11:03 AM
$MBX 🏥 VETmAb Biosciences, Inc. reports positive clinical proof-of-concept results for VMB-C001a in canine chronic inflammatory enteropathy, with 77.8% treatment success versus 30.0% for placebo, and eligibility for FDA CVM expanded conditional approval. Curated for market relevance
0 replies
Quantumup Oct 12, 10:52 AM
Stifel⬆️ $MBX's PT to $84 from $70 and reiterated Buy. $LLY $VKTX NVO KLRA GPCR Stifel said in its note: MBX is approaching its Part-C readout from the Ph.1 trial of MBX-4291 (monthly GLP-1/GIP) in obesity, following already strong indications from the Part-B portion that showed the intended characteristics of its smooth PK profile—high tolerability with a long half-life that allows for monthly dosing. Part C will be the first unblinded look following a unique, self-titrating regimen that reached -7% blinded weight loss/WL, with NO nausea or vomiting. While the primary goal of this trial is PK and tolerability, management believes concomitant WL in the 6-8% range, in line with other agents, would be sufficiently competitive in this vast obesity landscape—an achievable bar and one that should drive commensurate value capture. WL approaching 10% with similar/better tolerability than tirzepatide would offer an overall superior profile—potentially pushing MBX share beyond $80S.
0 replies
IPOtweet Oct 8, 1:39 PM
Despite recent pullback from a target hike, peptide biotech MBX rallied earlier on durable trial data, the start of a pivotal Phase 3, and encouraging obesity-program progress. Track new stocks on the go with IPO Pro: https://ipopro.renaissancecapital.com/ #IPO $MBX
0 replies
secfilings Oct 5, 1:53 PM
Peptide delivery is entering a new phase. Our latest SECFilings article looks at how $MBX, $MNKD and $PNGAF are exploring once-monthly dosing, inhaled GLP-1s and transdermal delivery—and why convenience is becoming a bigger part of the peptide market. https://www.secfilings.com/news/peptide-delivery-enters-a-new-phase-as-mbx-mnkd-and-pngaf-target-greater-convenience
0 replies
RandomInvestor777 Oct 4, 11:05 PM
$MBX I like this a bit, does anyone know when they dosed the cohort for obesity?
0 replies
Quantumup Oct 2, 12:50 PM
Guggenheim⬆️ $MBX's PT to $150 & reit'd Buy. ~Believes MBX 4291, should the Part C data show a once-monthly profile that is competitive with tirz—canvuparatide could make MBX a $8B+ Co.—rest of the obesity portfolio remain pot'l upside. $LLY VKTX NVO GPCR KLRA $ASND RHHBY Here's what Guggenheim said in its note to investors: https://x.com/Quantumup1/status/2106003575075676364?s=20
0 replies